Subject: Utilization
pattern of SUBA Itraconazole 130MG in real life scenario
Fungal infections today are among the most difficult diseases to manage in humans. The current burden of mycotic diseases in humans exceeds several million cases worldwide. Individual fungal diseases have profound impacts on human health.
Itraconazole is a triazole antifungal agent that has a broad spectrum of activity and is also well tolerated.
SUBA Itraconazole 130MG capsules are marketed by the Croslands team of Sun Pharmaceuticals Industries Ltd as Alcros SB 130MG capsules respcetively.
Although every product is marketed only after regulatory approval, it is important to know how it performs in day-to-day practice of individual medical practitioners. For this purpose, we have planed to conduct a cross sectional study to assess the real-life performance of Alcros SB 130MG in fungal infections.
We invite you to participate in this cross sectional study. All you need to do is to report on a standard form your experience with Alcros SB 130MG. Thus, this is not an experimental study.
If you agree to participate, you will need to provide assessment response, on to the standard data collection form (which we call DCF). A monitor will assist you in verifying and collecting the DCF.
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}